S

Seagen Inc
F:SGT

Watchlist Manager
Seagen Inc
F:SGT
Watchlist
Price: 208.6 EUR Market Closed
Market Cap: 39.4B EUR

EV/EBITDA
Enterprise Value to EBITDA

-65.8
Current
-61
Median
6.7
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-65.8
=
Enterprise Value
38.3B EUR
/
EBITDA
-677.2m USD
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
US
S
Seagen Inc
F:SGT
Average EV/EBITDA: 41.6
Negative Multiple: -65.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 621.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.9
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.4
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.3
11%
1.4
AU
CSL Ltd
ASX:CSL
13.3
8%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
172
N/A N/A
NL
argenx SE
XBRU:ARGX
63.1
807%
0.1

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-57.4
2-Years Forward
EV/EBITDA
-129.2
3-Years Forward
EV/EBITDA
172.1